We develop immuno-cancer-therapies.
What We Do
We are a clinical-stage biopharmaceutical company focuses on the development and application of T cell immunotherapies (TCR-T and CAR-T) against cancers that are predominant in Asian population.
Top Three Things to Communicate
#1 - The name of the company SCG is the initials of Singapore, China and Germany. It is a joint collaboration between the 3 countries.
#2 - We focus on the T cell immunotherapies, specifically TCR-T and CAR-T technology, which activate the patient’s own immunity system to eliminate the targeted cancer cells.
#3 - We target cancers that are predominant in Asian population.
Our Target Audience:
Our target audiences are our stakeholders including:
1. Cancer hospitals
2. biomedical industries
3. top medical professionals
5. Government Officials
6. Cancer Patients
7. Professional investors – VC, Private Equity fund managers, etc.
1. Choose colors that are frequently used in Medicine / Healthcare / cancer treatment.
2. Color choice should provide a sense of security and comfort for patients, doctors and other stakeholders.
Our Ideas and Additional Information:
1. The logo should indicate the core technology “cancer immunotherapy”, CAR-T, TCR-T Cell therapies.
2. Asia is the primary market focus.
3. International technology collaboration - Singapore, China and Germany.
4. One look at the logo knows roughly what this company does.